Hanns Mohler

Summary

Affiliation: Institute of Pharmacology and Toxicology
Country: Switzerland

Publications

  1. ncbi request reprint Endogenous benzodiazepine site Peptide ligands operating bidirectionally in vivo in neurogenesis and thalamic oscillations
    Hanns Mohler
    Institute of Pharmacology and Neuroscience Center, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland
    Neurochem Res 39:1032-6. 2014
  2. doi request reprint Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model
    Hanns Mohler
    Institute of Pharmacology, University of Zurich and, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH, Zurich, Switzerland
    Biochem Pharmacol 84:994-9. 2012
  3. doi request reprint The GABA system in anxiety and depression and its therapeutic potential
    Hanns Mohler
    Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, ETH Zurich, Winterthurerstr 190, CH 8057 Zurich, Switzerland
    Neuropharmacology 62:42-53. 2012
  4. doi request reprint Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition
    Hanns Mohler
    Institute of Pharmacology, University and ETH Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Biochem Pharmacol 81:1065-77. 2011
  5. doi request reprint Role of GABAA receptors in cognition
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology ETH Zurich, Switzerland
    Biochem Soc Trans 37:1328-33. 2009
  6. doi request reprint Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology, Zurich, Institute of Pharmacology, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Pharmacol Biochem Behav 90:58-64. 2008
  7. doi request reprint The alpha5(H105R) mutation impairs alpha5 selective binding properties by altered positioning of the alpha5 subunit in GABAA receptors containing two distinct types of alpha subunits
    Ela Balic
    Institute of Pharmacology and Toxicology, University of Zurich, Winterhurerstrasse, Zurich, Switzerland
    J Neurochem 110:244-54. 2009
  8. doi request reprint GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts
    Dietmar Benke
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Neuropharmacology 56:174-81. 2009
  9. ncbi request reprint GABA-based therapeutic approaches: GABAA receptor subtype functions
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland, and Laboratory of Genetic Neuropharmacology, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Curr Opin Pharmacol 6:18-23. 2006
  10. pmc Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?
    Philipp Singer
    Laboratory of Behavioural Neurobiology, ETH Zurich, 8603 Schwerzenbach, Switzerland
    Behav Neurosci 123:1012-27. 2009

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Endogenous benzodiazepine site Peptide ligands operating bidirectionally in vivo in neurogenesis and thalamic oscillations
    Hanns Mohler
    Institute of Pharmacology and Neuroscience Center, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland
    Neurochem Res 39:1032-6. 2014
    ..Nevertheless, the results open new perspectives on the regionally distinct endogenous modulation of GABA transmission via the benzodiazepine site. ..
  2. doi request reprint Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model
    Hanns Mohler
    Institute of Pharmacology, University of Zurich and, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH, Zurich, Switzerland
    Biochem Pharmacol 84:994-9. 2012
    ..Finally, repeated non-invasive sensory stimulation such as over-training or enriching the environment, are able to enhance the learning performance which underlines the reversibility of an obstructed neuronal plasticity in Ts65Dn mice...
  3. doi request reprint The GABA system in anxiety and depression and its therapeutic potential
    Hanns Mohler
    Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, ETH Zurich, Winterthurerstr 190, CH 8057 Zurich, Switzerland
    Neuropharmacology 62:42-53. 2012
    ..In addition, GABA(B) receptor antagonists may serve as potential antidepressants. This article is part of a Special Issue entitled 'Anxiety and Depression'...
  4. doi request reprint Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition
    Hanns Mohler
    Institute of Pharmacology, University and ETH Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Biochem Pharmacol 81:1065-77. 2011
    ..Thus, interventions at GlyT1 are highly effective in modifying multiple brain functions, and dissection of their respective mechanisms is expected to further maximize their therapeutic potential for human mental diseases...
  5. doi request reprint Role of GABAA receptors in cognition
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology ETH Zurich, Switzerland
    Biochem Soc Trans 37:1328-33. 2009
    ..The clinical proof-of-concept of a subtype-specific pharmacology is most advanced for the alleviation of cognitive dysfunctions in schizophrenia, based on the treatment of patients with an alpha(2)/alpha(3)-GABA(A) receptor ligand...
  6. doi request reprint Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology, Zurich, Institute of Pharmacology, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Pharmacol Biochem Behav 90:58-64. 2008
    ..Taken together, these results qualify distinct GABA-A receptor subtypes and GlyT1 as molecular targets for the development of a new pharmacology in the treatment of cognitive decline and psychotic symptoms...
  7. doi request reprint The alpha5(H105R) mutation impairs alpha5 selective binding properties by altered positioning of the alpha5 subunit in GABAA receptors containing two distinct types of alpha subunits
    Ela Balic
    Institute of Pharmacology and Toxicology, University of Zurich, Winterhurerstrasse, Zurich, Switzerland
    J Neurochem 110:244-54. 2009
    ..These findings imply an important role of histidine 105 in determining the position of the alpha5 subunit within the receptor complex by determining the affinity for assembly with the gamma2 subunit...
  8. doi request reprint GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts
    Dietmar Benke
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Neuropharmacology 56:174-81. 2009
    ..In beta3 (N265M) point-mutated mice the anxiolytic activity of valerenic acid was absent. Thus, neurons expressing beta3 containing GABA(A) receptors are a major cellular substrate for the anxiolytic action of valerian extracts...
  9. ncbi request reprint GABA-based therapeutic approaches: GABAA receptor subtype functions
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland, and Laboratory of Genetic Neuropharmacology, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Curr Opin Pharmacol 6:18-23. 2006
    ..Thus, a new pharmacology based on GABAA receptor subtype-specific actions is emerging...
  10. pmc Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?
    Philipp Singer
    Laboratory of Behavioural Neurobiology, ETH Zurich, 8603 Schwerzenbach, Switzerland
    Behav Neurosci 123:1012-27. 2009
    ....
  11. ncbi request reprint Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors
    Hanns Mohler
    Institute of Pharmacology, University of Zurich, Zurich, Switzerland
    J Neurochem 102:1-12. 2007
    ..These developments are reviewed with regard to the regulation of sleep, anxiety, memory, sensorimotor processing and post-natal developmental plasticity...
  12. ncbi request reprint Analysis of the presence and abundance of GABAA receptors containing two different types of alpha subunits in murine brain using point-mutated alpha subunits
    Dietmar Benke
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057, Switzerland
    J Biol Chem 279:43654-60. 2004
    ..This experimental approach provides the basis for a detailed analysis of the abundance of GABAA receptors containing heterologous alpha subunits on a brain regional level...
  13. ncbi request reprint Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice
    Carolien van Rijnsoever
    Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland
    J Neurosci 24:6785-90. 2004
    ..Thus, the chronic activation of alpha(5)-GABA(A) receptors is crucial for the normal development of sedative tolerance to diazepam, which manifests itself in conjunction with alpha1-GABA(A) receptors...
  14. ncbi request reprint Engineering embryonic stem cell derived glia for adenosine delivery
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Neurosci Lett 370:160-5. 2004
    ..1 +/- 6.0 ng per 10(5) cells per hour, an amount considered to be sufficient for seizure suppression. Our findings indicate that Adk-/- ES cells constitute a potential source for therapeutic adenosine releasing grafts...
  15. ncbi request reprint Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy
    Alexander Huber
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Neurosci Lett 329:289-92. 2002
    ....
  16. ncbi request reprint GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia
    Hanns Mohler
    Institute of Pharmacology, University of Zurich, Zurich, Switzerland
    J Recept Signal Transduct Res 26:731-40. 2006
    ..In this article, the contribution of GABAA receptor deficits to central nervous system disorders, in particular anxiety disorders, epilepsy, schizophrenia and insomnia, is reviewed...
  17. ncbi request reprint Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression
    Laetitia Gabernet
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstr 190, CH 8057 Zurich, Switzerland
    Neurosci Lett 373:79-84. 2005
    ..Thus, GlyT1 function is a controlling factor for an enhancement of the NMDA receptor response. These findings are of relevance for the development of GlyT1 inhibitory drugs...
  18. doi request reprint GABAergic analgesia: new insights from mutant mice and subtype-selective agonists
    Hanns Ulrich Zeilhofer
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Trends Pharmacol Sci 30:397-402. 2009
    ..First results raise hopes that such compounds will be active against inflammatory and neuropathic pain but devoid of many of the side-effects of the established benzodiazepine-like drugs...
  19. ncbi request reprint Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich
    Annu Rev Pharmacol Toxicol 44:475-98. 2004
    ....
  20. doi request reprint The rise of a new GABA pharmacology
    Hanns Mohler
    Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zurich, Winterthurerstr 190, CH 8057 Zurich, Switzerland
    Neuropharmacology 60:1042-9. 2011
    ..Today, the GABA pharmacology comprises selective hypnotics, non-sedative anxiolytics, memory enhancers and powerful analgesics. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'...
  21. ncbi request reprint Seizure suppression by adenosine-releasing cells is independent of seizure frequency
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 43:788-96. 2002
    ..We tested whether the suppression of seizures by adenosine-releasing grafts was independent of seizure frequency...